Order Article Reprints

Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, et al. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers. 2020; 12(2):473. https://doi.org/10.3390/cancers12020473

Tiako Meyo, Manuela, Anne Jouinot, Etienne Giroux-Leprieur, Elizabeth Fabre, Marie Wislez, Marco Alifano, Karen Leroy, Pascaline Boudou-Rouquette, Camille Tlemsani, Nihel Khoudour, and et al. 2020. "Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study" Cancers 12, no. 2: 473. https://doi.org/10.3390/cancers12020473

Tiako Meyo, M., Jouinot, A., Giroux-Leprieur, E., Fabre, E., Wislez, M., Alifano, M., Leroy, K., Boudou-Rouquette, P., Tlemsani, C., Khoudour, N., Arrondeau, J., Thomas-Schoemann, A., Blons, H., Mansuet-Lupo, A., Damotte, D., Vidal, M., Goldwasser, F., Alexandre, J., & Blanchet, B. (2020). Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 12(2), 473. https://doi.org/10.3390/cancers12020473